Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025

Core Insights - Transgene and BioInvent are presenting promising clinical results for BT-001, an oncolytic virus, in combination with pembrolizumab at the ESMO Annual Meeting [1][3][4] - The Phase I study indicates that BT-001 is well tolerated and shows anti-tumor activity in patients with advanced refractory tumors [5][7] Company Overview - Transgene is a biotech company focused on developing virus-based immunotherapies for cancer treatment, with BT-001 being one of its key assets [8][10] - BioInvent specializes in discovering and developing novel immune-modulatory antibodies for cancer therapy, utilizing its proprietary F.I.R.S.T.™ technology platform [10][11] Clinical Study Details - The Phase I/IIa study (NCT04725331) is a multicenter, open-label, dose-escalation trial evaluating BT-001 both as a single agent and in combination with pembrolizumab [5][4] - The study has shown that BT-001 can convert "cold" tumors into "hot" tumors, enhancing T-cell infiltration and PD(L)-1 expression in the tumor microenvironment [5][7] Treatment Efficacy - In the study, tumor shrinkage was observed in both injected and non-injected lesions, indicating a systemic effect [7] - Notably, two patients with resistant melanoma and heavily pretreated leiomyosarcoma exhibited partial responses lasting 6 and 16 months, respectively [7]